 |
Collected Strategies handles Exact Sciences as the cancer screening company is acquired by Abbott in a deal with an enterprise value of $23B.
Exact Sciences' offerings include Cologuard, non-invasive colorectal cancer screening option; and Oncotype DX, test for early-stage breast cancer.
The transaction makes Abbott, which will assume $1.8B in Exact Sciences’ net debt, a leader in the fast-growing $60B US cancer screening market, which is expected to rise due to population growth and the graying of America.
Abbott CEO Robert Ford said Exact Sciences’ “innovation, strong brand and customer-focused execution are unrivaled in the cancer diagnostics space.”
Madison, WI-based Exact Sciences is expected to generate more than $3B in revenues this year.
CEO Kevin Conroy will remain in an advisory role to support the transition into Abbott. "Together with Abbott, we can reach more patients, advance earlier detection, and deliver answers that change lives,” he said.
Collected Strategies has founding partner Jim Golden and managing director Tali Epstein representing Exact Sciences.
Burson Buchanan handles AAR Corp as the supplier of parts and services to the aviation market acquires a 65 percent stake in MRO Holdings.
The financial services industry thinks it needs more communications, when the real issue is credibility—and that requires entirely different solutions.
Starting out with the goal of creating a “different model” for communications, Tier One’s leaders discuss creating value for firms in financial/fintech, professional services and other high-tech industries.
Joele Frank pivoted from an early start as a biochemist to learn the ins and outs of financial PR and then put together a team that is a force to be reckoned with in the M&A field.
AI can give you all the data you’d ever need. But it can’t read a room. The knowledge that an experienced communicator has can result in a major advantage.
